addition, the Immediate Office is also responsible for data gathering, analysis, and dissemination; preparation of reports; budget projection, planning, execution and tracking; research development and communication of findings; and identification and utilization of new technology in managing the Bureau's workload and communicating with the Department, Regional Office, States, Territories, Tribes and the child care field. The Immediate Office also supports the unique program and planning needs of tribal grantees.

2. The Program Operations Division is responsible for Regional Liaison activities, including: communication on a regular basis with Regional Office staff; responding to questions on policy and other issues by consulting or referring to other staff; tracking progress of grantee programs in coordination with the Regions; collecting and maintaining information related to grantee program implementation, administrative data, technical assistance data, and technical assistance efforts; tracking program achievements, problems, and gaps; identifying latest trends and activities of major significance; preparing background material, fact sheets, and articles to provide information to Regional Offices, grantees and the general public; and tracking and supporting special initiatives. This unit also establishes partnerships with public and private entities to improve access to quality child care; coordinate program activities with other government and non-government agencies; and manages and oversees the Bureau's cooperative ventures with other entities.

3. The Policy Division develops, interprets and issues national policies and regulations governing Child Care and Development Fund (CCDF) programs. The Policy Division provides clarification of the statutes, regulations and policies; issues action transmittals and information memoranda; recommends and drafts legislative proposals; prepares briefing materials for hearings and testimony; updates the child care plan preprints; reviews and gives guidance to Regional Offices on CCDF plans and applications; oversees a data base of grantee plans; researches child care policy issues; coordinates policies and procedures with other Federal agencies; provides policy training, guidance and clarification to Regional Offices in carrying out policy functions; and manages controlled correspondence.

4. The Technical Assistance Division provides technical assistance to Regional Offices, States, Territories, and Tribes concerning CCDF in order to make affordable quality child care accessible to families. It provides leadership, coordination and contract management for technical assistance projects that comprise the Child Care Technical Assistance Network. This unit also oversees and supports national conferences, leadership forums, and Regional Office conferences. It oversees the development of technical assistance materials including publications.

Dated: October 20, 1998.

James Harrell,

Deputy Commissioner, Administration on Children, Youth and Families.

[FR Doc. 98–29191 Filed 10–30–98; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. 98F–0593, 98F–0674, and 98F–0707]

Dover Chemical Corp.; Withdrawal of Food Additive Petitions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of food additive petitions (FAP's 8B4614, 8B4613, and 8B4621) proposing that the food additive regulations be amended to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, which may contain not more than 2 percent by weight of triisopropanolamine, as an antioxidant and/or stabilizer for polymers (specifically, polyetherimide resins), olefin polymers, or polycarbonate and polyethylene phthalate polymers intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

SUPPLEMENTARY INFORMATION: In notices published in the **Federal Registers** of July 30, 1998 (63 FR 40720), August 19, 1998 (63 FR 44463), and August 25, 1998 (63 FR 45248), FDA announced that food additive petitions (FAP's 8B4614, 8B4613, and 8B4621) had been filed by Dover Chemical Corp., 3676 Davis Rd. NW., Dover, OH 44622. The petitions proposed to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenyethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, which may contain not more than 2 percent by weight of triisopropanolamine, as an antioxidant and/or stabilizer for polymers (specifically, polyetherimide resins), olefin polymers, or polycarbonate and polyethylene phthalate polymers intended for use in contact with food. Dover Chemical Corp. has now withdrawn the petitions (FAP's 8B4614, 8B4613, and 8B4621) without prejudice to a future filing (21 CFR 171.7).

Dated: October 16, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–29188 Filed 10–30–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Center for Biologics Evaluation and Research Medical Device Action Plan; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Center for Biologics Evaluation and Research Medical Device Action Plan. FDA is inviting interested parties, including industry, health professionals, patients and their advocacy groups to present their suggestions for improvements to the Center for Biologics Evaluation and Research's (CBER's) regulation of medical devices, or reasons to maintain the current systems to protect public health.

Date and Time: The meeting will be held on Tuesday, December 1, 1998, 9 a.m. to 5 p.m.

Location: The meeting will be held at Natcher Auditorium, Balcony B, National Institutes of Health, 8800 Rockville Pike, Bethesda, MD.

Contact: Kathy A. Eberhart, Center for Biologics Evaluation and Research (HFM–43), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–1317, FAX 301–827–3079, e-mail ''Eberhart@CBER.FDA.GOV''.

Registration and Requests for Oral Presentations: Send or fax written material and requests to make oral presentations to the contact person by Monday, November 16, 1998, and registration information (including name, title, firm name, address, telephone, and fax number), by Monday, November 23, 1998. Registration at the site will be done on a space available basis on the day of the meeting beginning at 8:30 a.m. There is no registration fee for the meeting. Space is limited, therefore, interested parties are encouraged to register early.

If you need special accommodations due to a disability, please contact Kathy A. Eberhart at least 7 days in advance.

SUPPLEMENTARY INFORMATION: Under section 406(b) of the Food and Drug Administration Modernization Act of 1997, CBER held two meetings with our external stakeholders. The first meeting was held on August 14, 1998, in Washington, DC (63 FR 39877, July 24, 1998), and the second one on August 28, 1998, in Oakland, CA (63 FR 39877, July 24, 1998). In addition, the FDA Pacific Regional Office sponsored a grassroots meeting on September 15, 1998 (63 FR 42052, August 6, 1998), in Irvine, CA, with the biotechnology industry.

A recurring theme during these meetings was a dissatisfaction with the handling of the medical devices regulated by CBER. Some important concerns were related to CBER procedures and standards for products similar to products regulated by the Center for Devices and Radiological Health. To address these concerns, CBER is developing a ''Device Action Plan'' to evaluate various options to change CBER's regulatory approaches for medical devices without creating a risk to the public health.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The meeting transcript will also be available on CBER's website at ''http://www.fda.gov/cber/minutes/workshop-min.htm''.

Dated: October 26, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–29185 Filed 10–30–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on November 17, 1998, 9 a.m. to 6 p.m.

Location: Corporate Bldg., conference room 020B, 9200 Corporate Blvd., Rockville, MD.

Contact Person: David Krause, Center for Devices and Radiological Health (HFZ–410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–3090, ext. 141, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12519. For up-to-date information on this meeting, please call the Information Line or access the Internet address at ''http://www.fda.gov/cdrh''.

Agenda: The committee will discuss and make recommendations on a proposal for the classification of preamendment wound dressing medical devices based on: (1) A proposed rule published in the **Federal Register** of September 19, 1989 (54 FR 38600); (2) comments received in response to the proposed rule; and (3) comments from the General and Plastic Surgery Devices Panel meeting of July 20, 1995. The committee will also discuss and make recommendations on the reclassification of preamendment class III topical oxygen devices for wound healing on extremities based on information received from a call for safety and effectiveness information under section 515(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360e(i)) published in the **Federal Registers** of August 14, 1995, and June 13, 1997 (60 FR 41986 and 62 FR 32355, respectively).

Procedure: On November 17, 1998, from 9:30 a.m. to 6 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 3, 1998. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10 a.m., and between approximately 4 p.m. and 4:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 3, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On November 17, 1998, from 9 a.m. to 9:30 a.m., the meeting will be closed to the public to permit FDA to present to the committee trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) regarding pending issues.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: October 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–29274 Filed 10–30–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Control of Pharmaceutical Production; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

SUMMARY: The Food and Drug Administration (FDA) is announcing a series of three public meetings sponsored by the Office of Regulatory Affairs (ORA), Pacific Region, and participated in by representatives from the Center for Drug Evaluation and Research (CDER), ORA's Division of Field Science, and the Pacific Region. The topic to be discussed is out-of-specification (OOS) laboratory test results, how to evaluate them and appropriate actions to take.

DATES: The public meetings are scheduled as follows:

1. Monday, November 16, 1998, from 8:30 a.m. to 3:30 p.m., in Bellevue, WA.